1. Home
  2. BDSX vs FATE Comparison

BDSX vs FATE Comparison

Compare BDSX & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BDSX
  • FATE
  • Stock Information
  • Founded
  • BDSX 2005
  • FATE 2007
  • Country
  • BDSX United States
  • FATE United States
  • Employees
  • BDSX N/A
  • FATE N/A
  • Industry
  • BDSX Precision Instruments
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BDSX Health Care
  • FATE Health Care
  • Exchange
  • BDSX Nasdaq
  • FATE Nasdaq
  • Market Cap
  • BDSX 115.4M
  • FATE 129.5M
  • IPO Year
  • BDSX 2020
  • FATE 2013
  • Fundamental
  • Price
  • BDSX $0.45
  • FATE $1.24
  • Analyst Decision
  • BDSX Strong Buy
  • FATE Hold
  • Analyst Count
  • BDSX 5
  • FATE 7
  • Target Price
  • BDSX $1.75
  • FATE $3.83
  • AVG Volume (30 Days)
  • BDSX 1.1M
  • FATE 1.6M
  • Earning Date
  • BDSX 08-07-2025
  • FATE 08-12-2025
  • Dividend Yield
  • BDSX N/A
  • FATE N/A
  • EPS Growth
  • BDSX N/A
  • FATE N/A
  • EPS
  • BDSX N/A
  • FATE N/A
  • Revenue
  • BDSX $74,463,000.00
  • FATE $13,335,000.00
  • Revenue This Year
  • BDSX $17.29
  • FATE N/A
  • Revenue Next Year
  • BDSX $29.33
  • FATE N/A
  • P/E Ratio
  • BDSX N/A
  • FATE N/A
  • Revenue Growth
  • BDSX 35.76
  • FATE 105.85
  • 52 Week Low
  • BDSX $0.17
  • FATE $0.66
  • 52 Week High
  • BDSX $2.04
  • FATE $5.92
  • Technical
  • Relative Strength Index (RSI)
  • BDSX 75.72
  • FATE 55.43
  • Support Level
  • BDSX $0.29
  • FATE $1.12
  • Resistance Level
  • BDSX $0.44
  • FATE $1.19
  • Average True Range (ATR)
  • BDSX 0.03
  • FATE 0.06
  • MACD
  • BDSX 0.02
  • FATE 0.02
  • Stochastic Oscillator
  • BDSX 98.04
  • FATE 71.43

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Share on Social Networks: